Verano Holdings (VRNO) Income from Non-Controlling Interests (2021 - 2023)

Verano Holdings' (VRNO) quarterly Income from Non-Controlling Interests came in at -$78000.0 in Q4 2023, down 200.0% on a QoQ basis from $78000.0 in Q3 2023.

Verano Holdings (VRNO) Income from Non-Controlling Interests (2021 - 2023) Analysis & Trends

Verano Holdings (VRNO) has 3 years of Income from Non-Controlling Interests data on file, last reported at -$78000.0 in Q4 2023.

  • On a quarterly basis, Income from Non-Controlling Interests changed N/A year-over-year to -$78000.0 in Q4 2023; TTM through Dec 2024 was -$78000.0, a N/A change from a year earlier, with the FY2022 full-year figure at $291000.0, down 88.4% from the prior year.
  • Income from Non-Controlling Interests for Q4 2023 stood at -$78000.0, down from $78000.0 in the prior quarter.
  • Over the last five years, Income from Non-Controlling Interests for VRNO reached as high as $594000.0 in Q4 2021 and fell as low as -$78000.0 in Q4 2023.
  • Historically, Income from Non-Controlling Interests has averaged $255666.7 across 3 years, with a median of $194500.0 in 2021.
Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Inc. Minority (Qtr)
1 Haleon 89.15 Bn 87.28 Bn - -
2 Teva Pharmaceutical Industries 35.85 Bn 32.11 Bn 1.97 Bn -
3 Zoetis 32.52 Bn 30.58 Bn 1.62 Bn -
4 Takeda Pharmaceutical 27.53 Bn 23.47 Bn 4.39 Bn 395,346.10
5 United Therapeutics 23.21 Bn 21.06 Bn 648.10 Mn -
6 RedHill Biopharma 21.76 Bn 21.76 Bn - -
7 Viatris 20.30 Bn 18.50 Bn 1.16 Bn -
8 Neurocrine Biosciences 17.74 Bn 16.42 Bn 800.70 Mn -12.70 Mn
9 Elanco Animal Health 12.59 Bn 12.16 Bn 785.00 Mn -
10 Verano Holdings 2.01 Bn 1.93 Bn 98.98 Mn -

Historic Data

Download Data
DateValue
Dec 31, 2023 -78,000.00
Sep 30, 2023 78,000.00
Mar 31, 2022 291,000.00
Dec 31, 2021 594,000.00
Sep 30, 2021 551,000.00
Jun 30, 2021 98,000.00